Ursodiol: Good drug makes good

Gastroenterology

Volumn 124, Issue 4, 2003, Pages 1139-1140

  Brentnall, Teresa A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; URSODEOXYCHOLIC ACID;

ADENOMATOUS POLYP; ANTIINFLAMMATORY ACTIVITY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CARCINOMA; DRUG MECHANISM; DRUG TOLERABILITY; EDITORIAL; HUMAN; LIVER FUNCTION; NONHUMAN; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TUMOR VOLUME; ULCERATIVE COLITIS;

EID: 0037382093     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2003.50181     Document Type: Editorial

References (19)

1. Rodrigues CMP, Kren BT, Steer CJ, Setchell KDR. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology 1995;109:1835-1844
2. Batta AK, Salen G, Holubec H, Brasitus TA, Alberts D, Earnest DL. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res 1998;58:1684-1687.
3. Pongracz J, Clark P, Neoptolemos JP, Lord JM. Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids. Int J Cancer 1995; 61:35-39.
4. Wali RK, Frawley BP Jr, Hartmann S, Roy HK, Khare S, ScaglioneSewell BA, Earnest DL, Sitrin MD, Brasitus TA, Bissonnette M. Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, beta-II, and zeta. Cancer Res 1995;55:5257-5264.
5. 2 expression in colonic tissue. Cancer Lett 1998;134:129-139.
6. Kopp R, Noelke B, Sauter G, Schildberg FW, Paumgartner G, Pfeiffer A. Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas. Cancer Res 1991;51:205-210.
7. Kusunoki M, Sakanoue Y, Hatada T, Yanagi H, Yamamura T, Utsunomiya J. Protein kinase C activity in human colonic adenoma and colorectal carcinoma. Cancer 1992;69:24-30.
8. Guillem JG, O'Brian CA, Fitzer CJ, Johnson MD, Forde KA, LoGerfo P, Weinstein IB. Studies on protein kinase C and colon carcinogenesis. Arch Surg 1987;122:1475-1478.
9. Sakanoue Y, Hatada T, Horai T, Shoji Y, Kusunoki M, Utsunomiya J. Protein kinase C activity of colonic mucosa in ulcerative colitis. Scand J Gastroenterol 1992;27:275-280.
10. 2 and diacylglycerol lipase are increased in human colorectal cancer. Br J Surg 1995; 82:475-478.
11. 2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut 1994;35: 1593-1598.
12. Mitsuyoshi H, Nakashima T, Sumida Y, Yoh T, Nakajima Y, Ishikawa H, Inaba K, Sakamoto Y, Okanoue T, Kashima K. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 1999;263:537-542.
13. Pardi DS, Loftus EV, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-893.
14. Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens A, Levine DS, Dean PJ, Kimmey MB, Perera DR, Rabinovitch PS. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992;103: 1611-1620.
15. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
16. Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS, Kowdley K, Stevens A, Crispin D, Emond M, Rubin CE. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996;110:331-338.
17. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999;94:1643-1649.
18. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995;22:1404-1408.
19. Wali RK, Stoiber D, Nguyen L, Hart J, Sitrin MD, Brasitus TA, Bissonnette M. Ursodeoxycholic acid inhibits the initiation and postinitation phases of azoxymethane-induce colonic tumor development. Cancer Epidemiol Biomarkers Prev 2002;11:1316-1321.